戴肯丘托通过促进血管生成来改善甲基甲酸诱导的慢性小肠粘膜炎
Peilin Li1,2, Yusuke Inoue1, Daichi Sadatomi3
1Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
戴肯丘托 (DKT) 在治疗化学疗法诱导的慢性小肠粘膜炎 (CIM) 中表现有前途. 这种传统医学通过促进愈合和屏障功能,改善了老鼠的生存率和肠道健康.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 综合医学是一个整体的医学.
背景情况:
- 慢性小肠粘膜炎 (CIM) 是化疗的严重并发症,治疗选择有限.
- 甲基 (MTX) 是一种常见的化疗剂,可以诱导CIM.
- 像戴肯丘托 (DKT) 这样的传统药物正在探索其治疗潜力.
研究的目的:
- 在大鼠模型中研究DKT对MTX诱导的CIM的治疗作用.
- 评估DKT对肠道组织学,屏障功能和血管生成的影响.
- 评估DKT在体外对肠道上皮细胞的细胞保护作用.
主要方法:
- 雄性斯普拉格-道利大鼠被分为对照,MTX,DKT-MTX和DKT组.
- 使用MTX诱导CIM,通过料口服DKT.
- 肠上皮细胞 (IEC-6) 用于体外细胞保护性试验.
主要成果:
- 在接受MTX治疗的老鼠中,DKT治疗显著改善了生存率,并减少了胃肠道症状和组织学损伤.
- 通过增强紧密结合蛋白和营养物质运输体,DKT恢复了粘膜的完整性,同时减少了氧化应激和细胞死亡.
- DKT促进了粘膜血管生成和再生,由基因表达分析证实.
结论:
- DKT通过增强血管生成,上皮再生和粘膜屏障功能来证明对MTX诱导的CIM的保护作用.
- DKT代表了一种潜在的辅助疗法,用于管理化疗引起的慢性肠道毒性.
- 对DKT的机制和临床疗效的进一步研究是有必要的.
更多相关视频
06:04Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
The Tumor Microenvironment
Drugs that Stabilize Microtubules
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
